EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

Google’s life sciences arm and DexCom, a San Diego maker of devices that track diabetes, just announced they’ll jointly develop a series of next-gen continuous glucose monitors. It’s a bold step in ...

For people with diabetes treated with insulin, Dexcom rtCGM is associated with significant improvements over patients’ lifetimes and is likely to be cost-saving to the NHS DexCom, Inc.

The company will unveil Dexcom Smart Basal, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...